Adenosquamous cancer of the pancreas: A multicenter retrospective study
Gastroenterol Hepatol. 2022 Aug-Sep;45(7):543-551.
doi: 10.1016/j.gastrohep.2021.12.006.
Epub 2021 Dec 21.
[Article in
English,
Spanish]
Affiliations
- 1 Servicio de Cirugía General, Hospital General Universitario, Alicante, Spain; ISABIAL: Instituto de Investigación Sanitaria y Biomédica, Alicante, Spain.
- 2 Servicio de Cirugía General, Complejo Hospitalario de Badajoz, Badajoz, Spain.
- 3 Servicio de Cirugía General, Hospital Universitario Miguel Servet, Zaragoza, Spain; Instituto de Investigación Sanitaria de Aragón, Zaragoza, Spain.
- 4 Servicio de Cirugía General, Hospital Universitario Miguel Servet, Zaragoza, Spain.
- 5 Servicio de Cirugía General, Hospital General Universitario, Alicante, Spain; Servicio de Anatomía Patológica, Hospital General Universitario, Alicante, Spain.
- 6 Servicio de Cirugía General, Hospital Universitario Miguel Servet, Zaragoza, Spain; Instituto de Investigación Sanitaria de Aragón, Zaragoza, Spain. Electronic address: marioserrradilla@hotmail.com.
- 7 Servicio de Cirugía General, Complejo Hospitalario de Badajoz, Badajoz, Spain; Universidad de Extremadura, Badajoz, Spain.
Abstract
Introduction:
Adenosquamous cancer of the pancreas (ASCP) is an aggressive, infrequent subtype of pancreatic cancer that combines a glandular and squamous component and is associated with poor survival.
Methods:
Multicenter retrospective observational study carried out at three Spanish hospitals. The study period was: January 2010-August 2020. A descriptive analysis of the data was performed, as well as an analysis of global and disease-free survival using the Kaplan-Meier statistic.
Results:
Of a total of 668 pancreatic cancers treated surgically, twelve were ASCP (1.8%). Patient mean age was 69.2±7.4 years. Male/female ratio was 1:1. The main symptom was jaundice (seven patients). Correct preoperative diagnosis was obtained in only two patients. Nine pancreatoduodenectomies and three distal pancreatosplenectomies were performed. 25% had major complications. Mean tumor size was 48.6±19.4mm. Nine patients received adjuvant chemotherapy. Median survival time was 5.9 months, and median disease-free survival was 4.6 months. 90% of patients presented recurrence. Ten of the twelve patients in the study (83.3%) died, with disease progression being the cause in eight. Of the two surviving patients, one is disease-free and the other has liver metastases.
Conclusion:
ASCP is a very rare pancreatic tumor with aggressive behavior. It is rarely diagnosed preoperatively. The best treatment, if feasible, is surgery followed by the standard chemotherapy regimens for pancreatic adenocarcinoma.
Keywords:
Adenoescamoso; Adenosquamous; Cancer; Cirugía; Cáncer; Pancreas; Páncreas; Surgery.
Copyright © 2021. Publicado por Elsevier España, S.L.U.
Publication types
-
Multicenter Study
-
Observational Study
MeSH terms
-
Adjuvants, Pharmaceutic
-
Aged
-
Carcinoma, Adenosquamous* / drug therapy
-
Carcinoma, Adenosquamous* / mortality
-
Carcinoma, Adenosquamous* / pathology
-
Carcinoma, Adenosquamous* / surgery
-
Female
-
Humans
-
Male
-
Middle Aged
-
Neoplasm Metastasis
-
Neoplasm Recurrence, Local
-
Pancreatic Neoplasms* / drug therapy
-
Pancreatic Neoplasms* / mortality
-
Pancreatic Neoplasms* / pathology
-
Pancreatic Neoplasms* / surgery
-
Retrospective Studies
-
Survival Analysis